Back to Search
Start Over
The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
- Source :
-
JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2009 Jul; Vol. 2 (7), pp. 645-54. - Publication Year :
- 2009
-
Abstract
- Objectives: We sought to compare the nephrotoxicity of the iso-osmolar contrast medium, iodixanol, to low-osmolar contrast media (LOCM).<br />Background: Contrast-induced acute kidney injury (CI-AKI) is a common cause of in-hospital renal failure. A prior meta-analysis suggested that iodixanol (Visipaque, GE Healthcare, Princeton, New Jersey) was associated with less CI-AKI than LOCM, but this study was limited by ascertainment bias and did not include the most recent randomized controlled trials.<br />Methods: We searched Medline, Embase, ISI Web of Knowledge, Google Scholar, Current Contents, and International Pharmaceutical Abstracts databases, and the Cochrane Central Register of Controlled Trials from 1980 to November 30, 2008, for randomized controlled trials that compared the incidence of CI-AKI with either iodixanol or LOCM. Random-effects models were used to calculate summary risk ratios (RR) for CI-AKI, need for hemodialysis, and death.<br />Results: A total of 16 trials including 2,763 subjects were pooled. There was no significant difference in the incidence of CI-AKI in the iodixanol group than in the LOCM group overall (summary RR: 0.79, 95% confidence interval [CI]: 0.56 to 1.12, p = 0.19). There was no significant difference in the rates of post-procedure hemodialysis or death. There was a reduction in CI-AKI when iodixanol was compared with ioxaglate (RR: 0.58, 95% CI: 0.37 to 0.92; p = 0.022) and iohexol (RR: 0.19, 95% CI: 0.07 to 0.56; p = 0.002), but no difference when compared with iopamidol (RR: 1.20, 95% CI: 0.66 to 2.18; p = 0.55), iopromide (RR: 0.93, 95% CI: 0.47 to 1.85; p = 0.84), or ioversol (RR: 0.92, 95% CI: 0.60 to 1.39; p = 0.68).<br />Conclusions: This meta-analysis including 2,763 subjects suggests that iodixanol, when compared with LOCM overall, is not associated with less CI-AKI. The relative renal safety of LOCM compared with iodixanol may vary based on the specific type of LOCM.
- Subjects :
- Aged
Aged, 80 and over
Consumer Product Safety
Evidence-Based Medicine
Female
Humans
Iohexol adverse effects
Iopamidol adverse effects
Ioxaglic Acid adverse effects
Kidney Diseases mortality
Kidney Diseases therapy
Male
Middle Aged
Odds Ratio
Osmolar Concentration
Randomized Controlled Trials as Topic
Renal Dialysis
Risk Assessment
Risk Factors
Contrast Media adverse effects
Kidney Diseases chemically induced
Triiodobenzoic Acids adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1876-7605
- Volume :
- 2
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- JACC. Cardiovascular interventions
- Publication Type :
- Academic Journal
- Accession number :
- 19628188
- Full Text :
- https://doi.org/10.1016/j.jcin.2009.05.002